Harmony Biosciences Holdings, Inc. Financials

Market Capitalization $1.84 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	12.26
Forward PE	9.85
Price to Sales TTM	$2.48
Price to Book MRQ	$2.56
Enterprise to Revenue	1.99
Enterprise to EBITDA	6.78

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	20.50%
Operating Margin	30.45%
Return on Assets TTM	12.81%
Return on Equity TTM	24.71%

Income Statement

Revenue TTM	$744,851,968
Revenue per Share TTM	$13.06
Quarterly Revenue Growth	19.50%
Gross Profit TTM	$583,526,976
EBITDA	$237,949,000
Net Income to Common TTM	$152,719,008
Diluted EPS TTM	$2.62
Quarterly Earnings Growth YoY	18.90%

Balance Sheet

Total Cash MRQ	$506,952,992
Total Cash per Share MRQ	$8.83
Total Debt MRQ	$
Total Debt to Equity MRQ	24.63
Current Ratio MRQ	3.67
Book Value per Share MRQ	$12.55

Cash Flow

Operating Cash Flow TTM	$222,667,008
Levered Free Cash Flow TTM	$143,407,632

HRMY Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	57,144,887
Float Shares	44,457,334
Avg 10 Volume	647,827
Avg 30 Volume	None
Shares Short	3,706,527
Short Ratio	5.76
Short % of Shares	14.16%
% Held by Insiders	11.09%
% Held by Institutions	92.80%

Stock Price Summary

Beta	0.87
Fifty Two Week Low	$26.47
Fifty Two Week High	$41.61
Fifty Two Week Change	1.18%
Day 50 MA	$32.93
Day 200 MA	$34.37

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date